Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.

A significant share of patients with phenylalanine hydroxylase (PAH) deficiency benefits from pharmacological doses of tetrahydrobiopterin (BH(4)), the natural PAH cofactor. Phenylketonuria (PKU) is hypothesized to be a conformational disease, with loss of function due to protein destabilization, and the restoration of enzyme function that is observed in BH(4) treatment might be transmitted by correction of protein misfolding. To elucidate the molecular basis of functional impairment in PAH deficiency, we investigated the impact of ten PAH gene mutations identified in patients with BH(4)-responsiveness on enzyme kinetics, stability, and conformation of the protein (F55L, I65S, H170Q, P275L, A300S, S310Y, P314S, R408W, Y414C, Y417H). Residual enzyme activity was generally high, but allostery was disturbed in almost all cases and pointed to altered protein conformation. This was confirmed by reduced proteolytic stability, impaired tetramer assembly or aggregation, increased hydrophobicity, and accelerated thermal unfolding--with particular impact on the regulatory domain--observed in most variants. Three-dimensional modeling revealed the involvement of functionally relevant amino acid networks that may communicate misfolding throughout the protein. Our results substantiate the view that PAH deficiency is a protein-misfolding disease in which global conformational changes hinder molecular motions essential for physiological enzyme function. Thus, PKU has evolved from a model of a genetic disease that leads to severe neurological impairment to a model of a treatable protein-folding disease with loss of function.

[1]  S. Petersen,et al.  L-phenylalanine binding and domain organization in human phenylalanine hydroxylase: a differential scanning calorimetry study. , 2002, Biochemistry.

[2]  Knut Teigen,et al.  Phosphorylation and Mutations of Ser16 in Human Phenylalanine Hydroxylase , 2002, The Journal of Biological Chemistry.

[3]  M. Thórólfsson,et al.  Allosteric mechanisms in ACT domain containing enzymes involved in amino acid metabolism , 2005, Amino Acids.

[4]  Frank Mueller,et al.  Preface , 2009, 2009 IEEE International Symposium on Parallel & Distributed Processing.

[5]  T. Flatmark,et al.  Probing the Role of Crystallographically Defined/Predicted Hinge-bending Regions in the Substrate-induced Global Conformational Transition and Catalytic Activation of Human Phenylalanine Hydroxylase by Single-site Mutagenesis* , 2004, Journal of Biological Chemistry.

[6]  P. Waters,et al.  Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. , 2000, Molecular Genetics and Metabolism.

[7]  Hristian,et al.  TETRAHYDROBIOPTERIN AS AN ALTERNATIVE TREATMENT FOR MILD PHENYLKETONURIA , 2002 .

[8]  Robert A. Copeland,et al.  Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis , 1996 .

[9]  R. Stevens,et al.  Structural Insight into the Aromatic Amino Acid Hydroxylases and Their Disease-Related Mutant Forms. , 1999, Chemical reviews.

[10]  M. Ugarte,et al.  Expression Analysis of Phenylketonuria Mutations , 2000, The Journal of Biological Chemistry.

[11]  J. M. Aarden,et al.  Structure/function relationships in human phenylalanine hydroxylase. Effect of terminal deletions on the oligomerization, activation and cooperativity of substrate binding to the enzyme. , 1996, European journal of biochemistry.

[12]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[13]  Aurora Martínez,et al.  Thermodynamic characterization of the binding of tetrahydropterins to phenylalanine hydroxylase. , 2004, Journal of the American Chemical Society.

[14]  R. Stevens,et al.  Structural basis of autoregulation of phenylalanine hydroxylase , 1999, Nature Structural Biology.

[15]  Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. , 2005, Molecular genetics and metabolism.

[16]  C. Scriver,et al.  The PAH gene, phenylketonuria, and a paradigm shift , 2007, Human mutation.

[17]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[18]  R. Stevens,et al.  Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Stevens,et al.  Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria , 1997, Nature Structural Biology.

[20]  R. Stevens,et al.  Structure of Tetrameric Human Phenylalanine Hydroxylase and Its Implications for Phenylketonuria* , 1998, The Journal of Biological Chemistry.

[21]  Belén Pérez,et al.  Phenylketonuria: Genotype–phenotype correlations based on expression analysis of structural and functional mutations in PAH , 2003, Human mutation.

[22]  T. Flatmark,et al.  Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. , 1995, The Biochemical journal.

[23]  P. Waters.  How PAH gene mutations cause hyper‐phenylalaninemia and why mechanism matters: Insights from in vitro expression , 2003, Human mutation.

[24]  C R Scriver,et al.  Monogenic traits are not simple: lessons from phenylketonuria. , 1999, Trends in genetics : TIG.

[25]  C. Sabatti,et al.  The Human Phenome Project , 2003, Nature Genetics.

[26]  P. Waters,et al.  Alterations in protein aggregation and degradation due to mild and severe missense mutations (A104D, R157N) in the human phenylalanine hydroxylase gene (PAH) , 1998, Human mutation.

[27]  K. Ingham,et al.  Thermodynamics of maltose binding protein unfolding , 1997, Protein science : a publication of the Protein Society.

[28]  Aurora Martínez,et al.  Activation of phenylalanine hydroxylase: effect of substitutions at Arg68 and Cys237. , 2003, Biochemistry.

[29]  T. Flatmark,et al.  Microheterogeneity of recombinant human phenylalanine hydroxylase as a result of nonenzymatic deamidations of labile amide containing amino acids. Effects on catalytic and stability properties. , 2000, European journal of biochemistry.

[30]  R. Stevens,et al.  Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations , 2004, Human mutation.

[31]  R. Stevens,et al.  The structural basis of phenylketonuria. , 1999, Molecular genetics and metabolism.

[32]  Knut Teigen,et al.  Phosphorylation and Mutations of Ser16 in Human Phenylalanine Hydroxylase , 2002, The Journal of Biological Chemistry.

[33]  L. Serrano,et al.  Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. , 2007, American journal of human genetics.

[34]  T. Flatmark,et al.  2.0A resolution crystal structures of the ternary complexes of human phenylalanine hydroxylase catalytic domain with tetrahydrobiopterin and 3-(2-thienyl)-L-alanine or L-norleucine: substrate specificity and molecular motions related to substrate binding. , 2003, Journal of molecular biology.

[35]  M. T. Flanagan.  Fluorescence spectroscopy , 1976, Nature.

[36]  Aurora Martínez,et al.  Structure of Phenylalanine Hydroxylase from Colwellia psychrerythraea 34H, a Monomeric Cold Active Enzyme with Local Flexibility around the Active Site and High Overall Stability* , 2007, Journal of Biological Chemistry.

[37]  Aurora Martínez,et al.  The activity of wild-type and mutant phenylalanine hydroxylase and its regulation by phenylalanine and tetrahydrobiopterin at physiological and pathological concentrations: an isothermal titration calorimetry study. , 2005, Molecular genetics and metabolism.

[38]  P. Guldberg,et al.  A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. , 1998, American journal of human genetics.

[39]  R C Stevens,et al.  Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. , 1998, European journal of biochemistry.

[40]  P. Picotti,et al.  Probing protein structure by limited proteolysis. , 2004, Acta biochimica Polonica.